# Cleveland HeartLab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cleveland-heartlab

- Industry: Healthcare
- Headquarters: Cleveland, US
- Website: www.clevelandheartlab.com
- Total disclosed funding: $18M
- Latest round: Series B (Aug 22, 2011)
- Investors on record: 2

## About

Cleveland HeartLab, Inc. is a specialized diagnostics company focused on cardiovascular health, providing advanced biomarker testing services to assess cardiovascular risk and improve patient outcomes.Cleveland HeartLab, Inc. was founded in 2009 in Cleveland, US. The company provides advanced diagnostic tests specifically for cardiovascular health, offering unique blood and urine biomarker tests. In 2021, MedEquity Capital acquired Cleveland HeartLab, Inc., although the financial terms were not disclosed. The company has completed 7 deals to date, with a total amount raised of USD 2.00 mn, all from its LATEST_ROUND of USD 2.00 mn funding.Cleveland HeartLab, Inc. specializes in advanced diagnostic services centered on cardiovascular health, offering unique blood and urine biomarker tests that provide an integrated assessment of cardiovascular risk. The company's core offerings include testing for biomarkers associated with inflammation and gut dysfunction, such as TMAO (Trimethylamine N-oxide), which has been linked to cardiovascular disease risk. These innovative tests enable healthcare providers to identify hidden risks that traditional lipid measurements may overlook, ultimately aiding in early diagnosis and intervention for patients at risk of heart disease. Cleveland HeartLab serves a diverse client base, including healthcare providers, hospitals, and health systems across the United States, and has established strategic partnerships with prominent organizations such as Quest Diagnostics and the Cleveland Clinic to enhance their testing capabilities and reach.Cleveland HeartLab generates revenue primarily through partnerships and direct B2B transactions with healthcare providers and institutions that utilize their diagnostic tests. The company’s transaction structure is founded on service agreements that allow healthcare facilities to access their biomarker testing services, which are critical for managing patient cardiovascular health. Revenue is derived from the volume of tests performed, with clients billed based on the specific services utilized, including flagship tests like TMAO testing. The firm’s pricing model is designed to accommodate various healthcare settings, offering flexibility to meet the needs of both large hospital systems and smaller clinics that require reliable cardiovascular risk assessments.Cleveland HeartLab, Inc. plans to leverage its recent funding from MedEquity Capital to support the development and launch of new diagnostic products aimed at enhancing cardiovascular health assessments. The company is also targeting expansion into additional healthcare markets across the US, with plans to establish partnerships that will broaden its service reach by 2024. The acquired funding will be directed towards enhancing research and development efforts, as well as increasing marketing initiatives to promote these upcoming products and services.

## Funding rounds

- Series B, Aug 22, 2011, $18M — HealthCare Ventures, Excel Venture Management

## Investors

- HealthCare Ventures — Series B
- Excel Venture Management (https://capitalatlas.ai/funds/excel-venture-management) — Series B